13 recruiting, 10 not yet recruiting, 2 active not recruiting. 25 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Recruiting 13, Not yet recruiting 10, Active not recruiting 2 |
| Phase 1 | 1 | Recruiting 1 |
Follow DLBCL - Diffuse Large B Cell Lymphoma: new trials by email Literature Review of DLBCL - Diffuse Large B Cell Lymphoma trials Research Report on DLBCL - Diffuse Large B Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement pirtobrutinib+MTX+immunolchemotherapy - Pirtobrutinib, Immunochemotherapy | Phase 2 | Not yet recruiting | Pengpeng Xu | 24 | 2026-09-01 | 2026-09-11 |
| Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma Pirtobrutinib, Sotoclax+/- Obinutuzumab (PSO) Combination for B cell lymphoma - DLBCL - Diffuse Large B Cell Lymphoma, Richter Transformation | Phase 2 | Not yet recruiting | Changzhou No.2 People's Hospital | 40 | 2026-08-30 | 2026-08-06 |
| Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL Pirtobrutinib+Pola-R-CHP - DLBCL - Diffuse Large B Cell Lymphoma, Pirtobrutinib | Phase 2 | Not yet recruiting | Changzhou No.2 People's Hospital | 48 | 2026-07-31 | 2026-08-06 |
| Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL Pirtobrutinib plus R-CHOP - DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy | Phase 2 | Not yet recruiting | Changzhou No.2 People's Hospital | 34 | 2026-07-30 | 2026-08-06 |
| Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab - DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma) | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 53 | 2026-07-25 | 2026-08-06 |
| Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma R-CHOP+Orelabrutinib, POLA-R-CHP+orelabrutinib, R-miniCHOP +orelabrutinib - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | Ou Bai, MD/PHD | 66 | 2026-06-16 | 2026-07-01 |
| Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP CL-Pola-R-CHP - DHL, THL | Phase 2 | Not yet recruiting | Ruijin Hospital | 28 | 2026-05-01 | 2026-04-27 |
| Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma MDX2003 - Lymphoma, Waldenström Macroglobulinemia (WM) | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 180 | 2026-04-13 | 2026-11-06 |
| Glofitamab Combined With CAR-T Therapy in R/R DLBCL Glofitamab, Obinutuzumab, Axicabtagene Ciloleucel - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 24 | 2026-03-01 | 2026-01-08 |
| Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) Orelabrutinib combined with standard immunochemotherapy with or without auto-HSCT - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | The Affiliated Hospital of Xuzhou Medical University | 30 | 2026-03-01 | 2026-07-02 |
| Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma Glofitamab; Polatuzumab vedotin; Zuberitamab; Cyclophosphamide; Doxorubicin; Prednisone - DLBCL - Diffuse Large B Cell Lymphoma, Chemo-free Therapy | Phase 2 | Not yet recruiting | Li Zhiming | 40 | 2026-01-15 | 2025-11-19 |
| Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma Epcoritamab, Loncastuximab Tesirine - Large B-cell Lymphoma, Relapse | Phase 2 | Recruiting | University of Miami | 26 | 2026-01-07 | 2026-10-15 |
| DALY II Japan/MB-CART2019.1 for DLBCL MB-CART2019.1 - DLBCL - Diffuse Large B Cell Lymphoma, CAR T Cell Therapy | Phase 2 | Recruiting | Miltenyi Biomedicine GmbH | 31 | 2025-12-11 | 2026-01-08 |
| Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL Pirtobrutinib, Lisaftoclax, Rituximab - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 29 | 2025-11-30 | 2025-12-01 |
| A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 Polatuzumab Vedotin, Rituximab, Cyclophosphamide - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 134 | 2025-06-20 | 2025-06-24 |
| Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ Zanubrutinib - Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | Virginia Commonwealth University | 21 | 2025-05-27 | 2026-01-23 |
| AZA Combined with R-GemOx for Elderly DLBCL Patients azacytidine, R-GemOx - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 80 | 2025-02-01 | 2025-01-16 |
| A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma Cerebral Spinal Fluid ctDNA - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 50 | 2024-12-11 | 2025-12-18 |
| Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes Chidamide plus R-CHOP - Chidamide, R-CHOP Chemotherapy | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 148 | 2024-08-20 | 2025-03-24 |
| Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study Mirabegron - NSCLC, SCLC | Phase 2 | Recruiting | Zhejiang Provincial People's Hospital | 260 | 2024-07-15 | 2024-08-02 |
Showing 20 of 25. Sign in to see all of them.
Dendritic Cell Sarcoma, Interdigitating (25) · Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, Follicular (3) · Recurrence (2) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Lung Neoplasms (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Pancreatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (25) · Histiocytic Disorders, Malignant (25) · Histiocytosis (25) · Lymphatic Diseases (25) · Neoplasms (25) · Neoplasms by Histologic Type (25) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphoma, Non-Hodgkin (8) · Lymphoproliferative Disorders (8) · Lymphoma (7) · Lymphoma, B-Cell (5) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
glofitamab (4) · Cyclophosphamide (3) · Doxorubicin (3) · Prednisone (3) · Rituximab (3) · pirtobrutinib (3) · polatuzumab vedotin (3) · Azacitidine (2) · obinutuzumab (2) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Lisaftoclax (1) · Methotrexate (1) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · Thiotepa (1) · Vincristine (1)
Changzhou No.2 People's Hospital (3) · The First Affiliated Hospital of Xiamen University (3) · Ruijin Hospital (2) · Abramson Cancer Center at Penn Medicine (1) · Australasian Leukaemia and Lymphoma Group (1) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Li Zhiming (1) · Memorial Sloan Kettering Cancer Center (1) · Miltenyi Biomedicine GmbH (1) · ModeX Therapeutics, An OPKO Health Company (1) · Ou Bai, MD/PHD (1) · Pengpeng Xu (1) · The Affiliated Hospital of Xuzhou Medical University (1) · The First Affiliated Hospital of Soochow University (1)
China (15) · United States (4) · Australia (2) · Israel (1) · Japan (1) · Netherlands (1) · Spain (1)
Bing Xu (1) · Bing Xu, PhD (1) · Bruce Hough, MD (1) · Jennifer Lue, MD (1) · Juan Alderuccio, MD (1) · Liu Yang, M.D. (1) · Stephen J. Schuster, MD (1) · Zhiming Li, Professor (1)